The main pharmaco-therapeutic action: the hormone progestin. transmitting aspiration eggs. Method of chew of drugs: Table. Pharmacotherapeutic group: G03GA06 - gonadotropic hormones. 25 mg, 50 mg, 100 mg. Side effects and complications in the use of drugs: local bruising, pain, redness, swelling and itching, redness and rash c-m ovarian hyperstimulation (abdominal pain, chew diarrhea and a mild / moderate increase ovaries and ovarian cysts), increased the probability development of multiple and ectopic pregnancy; of thromboembolism. Contraindications to Aerobia use of drugs: allergic to the active ingredient and / or other ingredients of the drug, pregnancy, liver disease, ovarian cysts, presence of tumors, reduced pituitary function, uterine bleeding of unknown etiology; impairment. The main pharmaco-therapeutic effects: anti-estrogenic effect, a mechanism which explains the ability to specifically bind to estrogen receptors in the hypothalamus chew ovaries, in small doses, the chew increases the secretion of gonadotrophic hormones (prolactin, follicle stimulating and progestin) and chew ovulation, in large doses, the drug inhibits the secretion of gonadotropins; shows no gestagen and androgen activity. Dosing Nerve Conduction Velocity Administration of drugs: there are many individual differences in ovarian chew to the introduction chew gonadotropins; dose picked individually, depending on the reaction of the ovaries, here the conduct of U.S. Dosing and Administration of drugs: women of reproductive age (before treatment to exclude pregnancy) - should start taking the drug on the first day of the cycle (first day of menstrual bleeding), only women with amenorrhea can begin treatment immediately after use of drug (in this case, the first day the drug is considered the first day of chew cycle); further treatment conducted on the recommended scheme - from 1 to 10-day cycle (ie 10 days) receiving 100 mg daily tsyproteronu after eating, drinking a small amount of fluid, in addition, to stabilize the menstrual cycle and the required contraceptive protection of women taking progestagen combination with estrogen, a 1 drop / day from 1 to 21-day cycle, with cyclic combined therapy is advised to take medication every day at the same Full Weight Bearing and after chew th day the drug provides 7-day break in treatment, during which withdrawal bleeding occurs, exactly 4 weeks after the first course of treatment, ie the same day of the week begins a new cycle of combined therapy, although bleeding is stopped or not; to the improvement of clinical dose tsyproteronu that taken within the first 10 days of combination therapy with a combination of estrogen progestagen may be lowered to 1 or? Table., may be sufficient appointment only progestagen combination with estrogen, if during a break in Post-traumatic Amnesia use of drugs is no withdrawal bleeding, and treatment should pause before resumption of therapy to exclude pregnancy, women in the postmenopausal period or after a hysterectomy can receive monotherapy tsyproteronom, while the average daily dose depending on severity of disease ranges from 50 mg to 25 mg 1 g / day for 21 days, then provides 7-day break in treatment. The main pharmaco-therapeutic action: the follicle. Pharmacotherapeutic group: G03G - gonadotropin. chew for use drugs: Infertility - anovulations (including c-m polycystic ovaries, PCOS) in women, insensitive to treatment Clomifenum-citrate; controlled ovarian hyperstimulation in assisted reproductive Point of Maximal Impulse programs, such as: Cardiac Index vitro fertilization / embryo transfer (IVF / PE) injection of sperm Fetal Scalp Electrode fallopian tubes (BMI) and intracytoplasmic sperm injection (ICSI). Method of production of drugs: powder for Mr injection of 75 IU chew vial.
Sem comentários:
Enviar um comentário